15 June 2009
Nancy Faigen
nancy.faigen@informausa.com
Merck & Co and
Schering-Plough are facing yet another lawsuit related to the promotion of the combination product Vytorin (ezetimibe plus simvastatin). A complaint has been filed by a Pennsylvania fund for active and retired state employees, alleging that the firms marketed Vytorin and Zetia (ezetimibe)...
Please Login to read the full article.
RELATED CONTENT
NEWS
- US Capitol Capsule: Health reform extends Medicare solvency, but programme to go bust by 2024
- J&J to pay $158M to settle Texas Medicaid fraud case
- FDA panel backs Merck's Vytorin in predialysis CKD, but rejects dialysis use
- Teva in US agrees to 2017 for Vytorin generic, as Merck has other pending cases
EVENTS
26 February 2012
Vancouver Convention Centre | Vancouver, BC, Canada
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
